Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Route of Administration, By Disease (Diabetes, Lysosomal Disorders), By Therapy Type, By Region, and Segment Forecasts, 2019 - 2025

  • ID: 4751746
  • Report
  • 145 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.,
  • AstraZeneca
  • BioMarin
  • Bristol-Myers Squibb
  • CymaBay Therapeutics
  • Merck KgaA
  • MORE
The global metabolic disorder therapeutics market size is expected to reach USD 88.93 billion by 2025. The market is anticipated to witness a CAGR of 7.56% during the estimated period. Rising incidences of diabetes, obesity, and hypercholesterolemia are expected to drive the market growth. It is estimated that by 2040, about 1 person in 11 people worldwide is likely to suffer from one of the aforementioned diseases.

Researchers estimate that the prevalence of metabolic diseases like obesity and diabetes is expected to double in the coming 2 decades, mainly in U.S. and Asian and Latin American countries. This, in turn, will help boost the overall market growth in the year to come. Furthermore, with better economic stability in developing countries, demand for novel therapeutics for one-time treatment has increased. This has made major companies in the global market to invest heavily in R&D to develop innovative therapy options. All these factors will contribute to the development of the market.

Further key findings from the study suggest:
  • Diabetes segment led the market in 2017, in terms of revenue generation,owing to higher prevalence and drug usage
  • Obesity segment is expected to register a CAGR of 9.27% over the forecast period owing to increasing prevalence as a result of sedentary lifestyle changes
  • Drug therapy was the most-preferred therapy due to its high reliability proven success and availability of various types of drugs to treat metabolic diseases
  • The segment is expected to maintain its dominance even during the forecast years due to the introduction of smart technology to deliver antidiabetic drug on a regulated basis
  • Key companies in this market are Novo Nordisk A/S;Sanofi S.A.; Boehringer Ingelheim GmbH; Eli Lilly and Company; Merck KgaA; Amgen, Inc.; AstraZeneca PLC; Actelion Pharmaceuticals Ltd.; Shire PLC; AbbVie, Inc. Biocon Ltd.;BioMarinPharmaceutical, Inc.; Bristol-Myers Squibb Company; Cipla, Inc.; and CymaBay Therapeutics, Inc.
  • Most of these companies are focusing on strategies, such as collaborations, expansion of product portfolios, and M&A to maintain their industry position
  • Oral route of administration was the key revenue-generating segment in 2017owing to its benefits, such as high reliability and ease of administration
  • North America was the largest regional market in 2017 and will maintain the trend in future due to the presence of key companies and rising cases of diabetes and obesity


Please Note: This report will be delivered within 48 hours of ordering.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.,
  • AstraZeneca
  • BioMarin
  • Bristol-Myers Squibb
  • CymaBay Therapeutics
  • Merck KgaA
  • MORE
Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 Internal database
1.2 Research Methodology
1.3 Geographic scope & assumptions
1.4 Region-wise market calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based segment share calculation
1.6 List of Secondary Sources

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Increasing prevalence of metabolic disorders
3.1.1.2 Collaborations between manufacturers and research facilities
3.1.1.3 Government initiatives
3.1.2 Market restraint analysis
3.1.2.1 Expensive rare disease therapies
3.1.2.2 Ambiguous regulatory policies
3.2 Penetration & growth prospect mapping
3.3 Metabolic Disorder Therapeutics - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter’s

Chapter 4 Metabolic Disorder Therapeutics Market: Disease Estimates & Trend Analysis
4.1 Metabolic Disorder Therapeutics Market by Disease, Movement Analysis
4.2 Lysosomal Storage Diseases
4.2.1 Lysosomal storage diseases market estimates and forecast, 2014 - 2025 (USD Billion)
4.2.2 Gaucher’s Disease
4.2.2.1 Gaucher’s disease market estimates and forecast, 2014 - 2025 (USD Billion)
4.2.3 Metachromatic leukodystrophy
4.2.3.1 Metachromatic leukodystrophy market estimates and forecast, 2014 - 2025 (USD Billion)
4.2.4 Hurler - Scheie Disease
4.2.4.1 Hurler - Scheie disease market estimates and forecast, 2014 - 2025 (USD Billion)
4.2.5 Sanfilipo A disease
4.2.5.1 Sanfilipo A disease market estimates and forecast, 2014 - 2025 (USD Billion)
4.2.6 Other diseases
4.2.6.1 Others diseases market estimates and forecast, 2014 - 2025 (USD Billion)
4.3 Diabetes
4.3.1 Diabetes market estimates and forecast, 2014 - 2025 (USD Billion)
4.4 Obesity
4.4.1 Obesity market estimates and forecast, 2014 - 2025 (USD Billion)
4.5 Inherited Metabolic Disorders
4.5.1 Inherited metabolic disorders market estimates and forecast, 2014 - 2025 (USD Billion)
4.6 Hypercholesterolemia
4.6.1 Hypercholesterolemia market estimates and forecast, 2014 - 2025 (USD Billion)

Chapter 5 Metabolic Disorder Therapeutics Market: Therapy Type Estimates & Trend Analysis
5.1 Metabolic Disorder Therapeutics Market: Therapy Type Movement Analysis
5.2 Enzyme Replacement Therapy
5.2.1 Enzyme replacement therapy market estimates and forecast, 2014 - 2025 (USD Billion)
5.3 Cellular Transplantation
5.3.1 Cellular transplantation market estimates and forecast, 2014 - 2025 (USD Billion)
5.4 Small Molecule-Based Therapy
5.4.1 Small molecule based therapy market estimates and forecast, 2014 - 2025 (USD Billion)
5.5 Substrate Reduction Therapy
5.5.1 Substrate reduction therapy market estimates and forecast, 2014 - 2025 (USD Billion)
5.6 Gene Therapy
5.6.1 Gene therapy market estimates and forecast, 2014 - 2025 (USD Billion)
5.7 Drug Therapy
5.7.1 Drug therapy market estimates and forecast, 2014 - 2025 (USD Billion)

Chapter 6 Metabolic Disorder Therapeutics Market: Route of Administration Estimates & Trend Analysis
6.1 Metabolic Disorder Therapeutics market: route of administration movement analysis
6.2 Oral Administration
6.2.1 Oral administration market estimates and forecast, 2014 - 2025 (USD Billion)
6.3 Parenteral Administration
6.3.1 Parenteral administration market estimates and forecast, 2014 - 2025 (USD Billion)
6.4 Other route of administration
6.4.1 Other route of administration market estimates and forecast, 2014 - 2025 (USD Billion)

Chapter 7 Metabolic Disorder Therapeutics Market: Regional Outlook
7.1 Metabolic Disorder Therapeuticsmarket share by region, 2017 & 2025 (USD Billion)
7.2 North America
7.2.1 North America market estimates and forecast, 2014 - 2025 (USD Billion)
7.2.2 U.S
7.2.2.1 U.S metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
7.2.3 Canada
7.2.3.1 Canada metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
7.3 Europe
7.3.1 Europe metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
7.3.2 Germany
7.3.2.1 Germany metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
7.3.3 U.K.
7.3.3.1 U.K. metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
7.4 Asia Pacific
7.4.1 Asia Pacific metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
7.4.2 Japan
7.4.2.1 Japan metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
7.4.3 China
7.4.3.1 China metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
7.5 Latin America
7.5.1 Latin America metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
7.5.2 Brazil
7.5.2.1 Brazil metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
7.6 MEA
7.6.1 MEA metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
7.6.2 South Africa
7.6.2.1 South Africa metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)

Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Market Participation Categorization
8.3 Company Profiles
8.3.1 Novo Nordisk
8.3.1.1 Company overview
8.3.1.2 Financial performance
8.3.1.3 Product benchmarking
8.3.1.4 Strategic initiatives
8.3.2 Eli Lilly and Company
8.3.2.1 Company overview
8.3.2.2 Financial Performance
8.3.2.3 Product benchmarking
8.3.2.4 Strategic initiatives
8.3.3 Shire Plc
8.3.3.1 Company overview
8.3.3.2 Financial performance
8.3.3.3 Product benchmarking
8.3.3.4 Strategic initiatives
8.3.4 Sanofi
8.3.4.1 Company overview
8.3.4.2 Financial performance
8.3.4.3 Product benchmarking
8.3.4.4 Strategic initiatives
8.3.5 Merck KgaA
8.3.5.1 Company overview
8.3.5.2 Financial performance
8.3.5.3 Product benchmarking
8.3.5.4 Strategic initiatives
8.3.6 AstraZeneca
8.3.6.1 Company overview
8.3.6.2 Financial performance
8.3.6.3 Product benchmarking
8.3.6.4 Strategic initiatives
8.3.7 AbbVie Inc.,
8.3.7.1 Company overview
8.3.7.2 Financial performance
8.3.7.3 Product benchmarking
8.3.7.4 Strategic initiatives
8.3.8 Actelion Pharmaceuticals Ltd
8.3.8.1 Company overview
8.3.8.2 Financial performance
8.3.8.3 Product benchmarking
8.3.8.4 Strategic initiatives
8.3.9 Amgen Inc.,
8.3.9.1 Company overview
8.3.9.2 Financial performance
8.3.9.3 Product benchmarking
8.3.9.4 Strategic initiatives
8.3.10 Biocon
8.3.10.1 Company overview
8.3.10.2 Financial performance
8.3.10.3 Product benchmarking
8.3.10.4 Strategic initiatives
8.3.11 BioMarin
8.3.11.1 Company overview
8.3.11.2 Financial performance
8.3.11.3 Product benchmarking
8.3.11.4 Strategic initiatives
8.3.12 Boehringer Ingelheim
8.3.12.1 Company overview
8.3.12.2 Financial performance
8.3.12.3 Product benchmarking
8.3.12.4 Strategic initiatives
8.3.13 Bristol-Myers Squibb
8.3.13.1 Company overview
8.3.13.2 Financial performance
8.3.13.3 Product benchmarking
8.3.13.4 Strategic initiatives
8.3.14 Cipla Inc.,
8.3.14.1 Company overview
8.3.14.2 Financial performance
8.3.14.3 Product benchmarking
8.3.14.4 Strategic initiatives
8.3.15 CymaBay Therapeutics
8.3.15.1 Company overview
8.3.15.2 Financial performance
8.3.15.3 Product benchmarking
8.3.15.4 Strategic Initiatives
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Novo Nordisk
  • Eli Lilly and Company
  • Shire Plc
  • Sanofi
  • Merck KgaA
  • AstraZeneca
  • AbbVie Inc.,
  • Actelion Pharmaceuticals Ltd
  • Amgen Inc.,
  • Biocon
  • BioMarin
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cipla Inc.,
  • CymaBay Therapeutics
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4751746
Adroll
adroll